A Clinical Trial of TQ05105 Tablets Combined With TQB3617 Capsules in the Treatment of Myelofibrosis (MF)



Status and phase

Phase 2
Phase 1




Drug: TQB3617 Capsules
Drug: TQ05105 Tablets

Study type


Funder types




Details and patient eligibility


This is an open, single-arm, multi-center clinical study designed to evaluate the efficacy and safety of TQ05105 Tablets combined with TQB3617 Capsules in patients with intermediate- and high-risk Myelofibrosis.


78 estimated patients




18+ years old


No Healthy Volunteers

Inclusion criteria

  • Voluntary and signed informed consent, good compliance.
  • Age: 18 or above (when signing the informed consent form); Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of 0 or 2; Life expectancy ≥ 24 weeks.
  • Patients diagnosed with Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post PV MF), or post essential thrombocythemia myelofibrosis (post ET MF)
  • According to the dynamic international prognostic scoring system (DIPSS), patients with intermediate or high risk of bone marrow fibrosis were evaluated.
  • Patients with poor efficacy of JAK inhibitors (for phase Ib and phase II cohort 2)
  • Patients who had not received JAK inhibitor treatment (for phase II cohort 1).
  • Spleen enlargement.
  • Peripheral blood primary cells and bone marrow primary cells were ≤10%.
  • No growth factor, colony stimulating factor, thrombopoietin or platelet transfusion was received within 2 weeks before the examination, and the blood routine indexes met the requirements within 7 days before the first administration.
  • The Main organ function is normal.
  • Men and women of childbearing age should agree to use contraceptive measures (such as intrauterine devices, contraceptives, or condoms) during the study period and within 6 months after the end of the study. Serum human chorionic gonadotrophin (HCG) test is not negative within 7 days before the first administration and must be non-lactating patients.

Exclusion criteria

  • Patients who have previously received allogeneic stem cell transplantation, or received autologous stem cell transplantation within 3 months before the first administration, or recently planned stem cell transplantation;
  • Previous treatment with BET inhibitors;
  • Patients who have previously undergone splenectomy, or received splenic radiotherapy within 6 months before the first administration;
  • Use of any MF medications, any immunomodulators, androgens, any immunosuppressive agents, erythropoietin, aspirin > 100 mg/day within 2 weeks prior to first administration;
  • Other malignancies within 3 years prior to first administration or currently present.
  • Patients with multiple factors (such as inability to swallow, postoperative gastrointestinal resection, acute and chronic diarrhea, intestinal obstruction, etc.) affecting oral or absorption of drugs;
  • Major surgical treatment or significant traumatic injury within 4 weeks prior to first administration;
  • Presence of congenital bleeding disorder and congenital coagulopathy;
  • Patients who had arterial/venous thrombosis events within 6 months before the first administration.
  • Have a history of mental drug abuse, or have a mental disorder.
  • Active or uncontrolled severe infection;
  • Active hepatitis B virus (HBV) infection, or hepatitis C virus (HCV) infection and HCV RNA positive, or active Corona Virus Disease 2019 (COVID-19) infection;
  • Patients with grade III or above congestive heart failure, unstable angina pectoris or myocardial infarction, or arrhythmia requiring treatment, or QT interval prolongation within 6 months before the first administration;
  • Unsatisfactory blood pressure control despite standard therapy;
  • Patients with renal failure requiring hemodialysis or peritoneal dialysis;
  • Patients newly diagnosed with pulmonary interstitial fibrosis or drug-related interstitial lung disease within 3 months before the first administration;
  • Patients with a history of immunodeficiency disease or organ transplantation;
  • Patients with epilepsy requiring treatment;
  • Patients who have received Chinese patent medicines with anti-tumor indications specified in the approved drug package insert of China National Medical Products Administration (NMPA) within 2 weeks before the first administration;
  • Patients with uncontrolled pleural effusion, pericardial effusion or ascites;
  • There was a history of attenuated live vaccine inoculation within 4 weeks before the first administration, or attenuated live vaccine inoculation was planned during the study period.
  • People with known hypersensitivity to the study drug and excipients;
  • Patients diagnosed as active autoimmune diseases within 2 years before the first administration;
  • Those who participated in and used other anti-tumor clinical trial drugs within 4 weeks before the first administration (except JAK inhibitor-related clinical trials).
  • According to the judgment of the investigators, some situations seriously endanger the safety of the subjects or affect the subjects to complete the study.

Trial design

Primary purpose




Interventional model

Single Group Assignment


None (Open label)

78 participants in 1 patient group

TQ05105 Tablets + TQB3617 Capsules
Experimental group
TQ05105 Tablets combined with TQB3617 Capsules, orally administered. 21 days as a treatment cycle.
Drug: TQ05105 Tablets
Drug: TQB3617 Capsules

Trial contacts and locations



Central trial contact

Chunkang Chang, Doctor; Luxi Song, Master

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems